DAVID GRANOVSKY

Archive for August 26th, 2009|Daily archive page

Stem Cell Stock Index

In BUSINESS OF STEM CELLS on August 26, 2009 at 9:48 pm

Today the Index Value closed at $4.87, up 0.05 — a gain of 1.04%.

The index value climbed to 1.3379 from 1.3242 with an associated index market cap of $4.028 Billion.

Company Ticker Last Change %
Advanced Cell Technology ACTC.OB $0.00 $0.00 0
Aastrom Biosciences ASTM $0.44 -$0.019 -4.14%
AVI Biopharma AVII $1.42 $0.03 2.16%
BrainStorm Cell Therapeutics BCLI.OB $0.11 -$0.005 -4.55%
CRYO-CELL International CCEL.OB $1.96 -$0.05 -2.49%
Cryo-Save CRYO.L $58.00 $0.00 0.00
Cytori Therapeutics CYTX $3.21 $0.00 0.00
Geron Corporation GERN $6.93 $0.37 5.64%
ThermoGenesis KOOL $0.67 $0.0101 1.53%
MultiCell Technologies MCET.OB $0.03 -$0.0032 -10.09%
NeoStem, Inc. NBS $1.78 $0.08 4.71%
Opexa Therapeutics Inc. OPXA $1.47 $0.06 4.26%
Osiris Therapeutics, Inc. OSIR $14.49 $0.34 2.40%
Ortec International, Inc. OTCI.OB $0.00 $0.00 0
Stem Cell Thera SSS.V $0.13 $0.005 4.17%
StemCells STEM $1.70 $0.08 4.94%

DARA, ASC, ICTY, LDSR, CMLS, ONT

In BUSINESS OF STEM CELLS on August 26, 2009 at 7:08 pm

DARA BIOSCIENCES INCORPORATED (NASDAQ: DARA) “Up 31.24% on Wednesday” Detailed Quote: http://www.otcpicks.com/quotes/DARA.php

stemcells_money1DARA BioSciences Inc. (“DARA”) is a Raleigh, North Carolina based development-stage pharmaceutical company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND’s (Investigational New Drug) Applications from the US FDA. One of these drug candidates KRN5500 has successfully completed a Phase 2a clinical trial treating cancer patients for neuropathic pain. It has a portfolio of drug candidates for neuropathic pain, type 2 diabetes, and psoriasis.

DARA News: August 4 – DARA BioSciences, Inc. and America Stem Cell, Inc. Collaborate On Stem Cell Research DARA BioSciences, Inc. (Nasdaq: DARA) announced that the Company is collaborating with America Stem Cell (“ASC”) to expand on observations from recent preclinical studies showing that dipeptidylpeptidase (DPPIV) inhibitors improve the efficiency of hematopoietic stem cell (HSC) transplants. HSC transplants are used as a therapeutic approach for many malignant and non-malignant hematological disorders.

ASC will expand on these previous observations with preclinical studies utilizing potent and selective DPPIV inhibitors obtained from DARA BioSciences. The goal of this collaboration is to accelerate the translation of this approach to the clinic for the benefit of many patients in need of a HSC transplant.

ABOUT AMERICA STEM CELL, INC.

America Stem Cell, Inc. (“ASC”) is a privately held biotechnology company based in Carlsbad, CA, and is dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cells. The Company possesses two key technology platforms – ASC-101 and ASC-201 – that are designed to improve the engraftment of stem cells to target organs and increase their therapeutic potential.

via ICTY, LDSR, CMLS, ONT, DARA, August 6 Stocks to Watch from OTCPicks.com.

Dominick Dunne, dies in NYC at 83

In CELEBRITIES & STEM CELLS on August 26, 2009 at 6:57 pm

“Dunne had traveled to Germany and the Dominican Republic for experimental stem cell treatments to fight his cancer”

Dominick Dunne, who wrote stories of shocking crimes among rich and famous, dies in NYC at 83

NEW YORK (AP) — Author Dominick Dunne, who told stories of shocking crimes among the rich and famous through his magazine articles and best-selling novels such as “The Two Mrs. Grenvilles,” died Wednesday in his home at age 83.

https://i2.wp.com/latimesblogs.latimes.com/photos/uncategorized/dunne.jpg

Dunne Received Stem Cells for Bladder Cancer

Dunne’s son, actor-director Griffin Dunne, said in a statement released by Vanity Fair magazine that his father had been battling bladder cancer. But the cancer had not prevented Dunne from working and socializing, his twin passions.

In September 2008, against the orders of his doctor and the wishes of his family, Dunne flew to Las Vegas to attend the kidnap-robbery trial of O.J. Simpson, a postscript to his coverage of Simpson’s 1995 murder trial, which spiked Dunne’s considerable fame.

In the past year, Dunne had traveled to Germany and the Dominican Republic for experimental stem cell treatments to fight his cancer. He wrote that he and actress Farrah Fawcett were in the same cancer clinic in Bavaria but didn’t see each other. Fawcett, a 1970s sex symbol and TV star of “Charlie’s Angels,” died in June at age 62.

Dunne discontinued his column at Vanity Fair to concentrate on finishing another novel, “Too Much Money,” which is to come out in December. He also made a number of appearances to promote a documentary film about his life, “After the Party,” which was being released on DVD.

via The Associated Press: AP News in Brief.

MSC2009 – Adult Stem Cell Conference – General Biotechnology

In BUSINESS OF STEM CELLS on August 26, 2009 at 6:29 pm

CLEVELAND, Ohio –MSC2009, the regenerative medicine and adult stem cell therapy conference, on Monday started a three-day gathering that features a largely academic audience from as far away as Brazil, Iran and Russia discussing innovations and research in the field.

Vodpod videos no longer available.

General Biotechnology is developing preservation methods for an array of cell types including stem cells. The company makes a series of devices dealing with stem cells, including a biomaterial that helps support fragile cells, and products that harvest and test stem cells taken from umbilical cord blood.

via http://www.medcitynews.com/index.php/2009/08/video-3-stem-cell-businesses-at-msc2009/

MSC2009 – Adult Stem Cell Conference – Vitacyte

In BUSINESS OF STEM CELLS on August 26, 2009 at 6:22 pm

CLEVELAND, Ohio –MSC2009, the regenerative medicine and adult stem cell therapy conference, on Monday started a three-day gathering that features a largely academic audience from as far away as Brazil, Iran and Russia discussing innovations and research in the field.

Vodpod videos no longer available.

VitaCyte is a startup cell-isolation company that has started using stem cells in its product lines, which include manufacturing reagents, kits and purified cells to be used in the academic or commercial setting. The company uses enzymes to isolate certain cells in the hopes of speeding the production and discovery process in a lab.

via  http://www.medcitynews.com/index.php/2009/08/video-3-stem-cell-businesses-at-msc2009/

MSC2009 – Adult Stem Cell Therapy Conference – Pluristem

In BUSINESS OF STEM CELLS on August 26, 2009 at 6:10 pm

CLEVELAND, Ohio –MSC2009, the regenerative medicine and adult stem cell therapy conference, on Monday started a three-day gathering that features a largely academic audience from as far away as Brazil, Iran and Russia discussing innovations and research in the field.

Vodpod videos no longer available.

Pluristem Therapeutics is a publicly traded company that uses adult stem cells and is developing its first treatment, which would address peripheral artery disease. In addition, the company thinks it can development product to help other afflictions including Crohn’s disease, multiple sclerosis and ischemic stroke.

Its peripheral artery disease treatment, PLX-PAD, is in the midst of Phase I clinical trials in the United States and Europe, and the company planned to present details of that study at the conference.

via Video: 3 stem cell businesses at MSC2009 : MedCity News.

Top Pro Trader Brian Shannon – Stem Cell Stocks

In BUSINESS OF STEM CELLS on August 26, 2009 at 6:07 pm

Brian: I understand the fundamentals of a lot of companies. It’s a fine balance. For example, I’ve traded the stem cell stocks over the past few election cycles. Bush was going to veto them and Obama promised to give federal funding to stem cell companies. So, watching the television and headlines made me realize this issue was coming into the public perception. Then I look at the charts to see whether the stocks have already made a move. If they have, I will dismiss them. If not, I will start stalking the stocks and wait for evidence that larger players are accumulating the shares. Then I will establish positions as the stocks start to break out before big volume starts coming in.

But you have to be very active and attentive. In the case of stem cells, the stocks plummeted the day Obama signed the bill. It was a classic case of “buy the rumor, sell the news.” The problem is these companies are years away from making money or bringing things to market. Ordinary investors at home don’t recognize this. They just think, “Wow. That’s great news. I’m going to invest because maybe it can cure diseases.” This person is going to be late to the game if they are investing this way. Unfortunately, it’s simply a matter of not understanding how the stock market works.

via Top Pro Trader Brian Shannon | Day Trading on NYSE.

Cord Blood America Inc. (OTC:CBAI) Top Traded OTC

In BUSINESS OF STEM CELLS on August 26, 2009 at 6:02 pm

Cord Blood America Inc. (OTC:CBAI) Is The Top Traded OTC Stock

stemcells_money1HARD TO TREAT DISEASES (PINK:HTDS) and Universal Detection Technology (OTC:UNDT) Round Out Top Three Volume Gainers During Morning Trading Hours

Dallas, TX 8/13/2009 02:35 PM GMT (TransWorldNews)

Dallas, TX – Penny Stock Pick Alert is a penny stock newsletter that is pleased to alert investors of top stocks on the move.

Cord Blood America Inc. (OTC:CBAI) is up 3% to $0.0032 on huge volume of 4.50 million shares within first hour of trade. On August 11, 2009, Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced that work has begun at its new, 17,000 square foot facility in Las Vegas for conversion into a state-of-the-art laboratory for the storage of stem cells and for research and development.

HARD TO TREAT DISEASES (PINK:HTDS) is also moving higher by 23% at $0.0163 on very unusual volume of 92 million shares . Yesterday August 12, 2009 Hard to Treat Diseases, Inc. (HTDS:PK), announced that Hard To Treat Diseases (HTDS.PK) Completes IP Ownership Filings With U.S. Patent and Trademark Office.

via Cord Blood America Inc. (OTC:CBAI) Is The Top Traded OTC.

Cord Blood America Retires $1.6 Million in Debt

In BUSINESS OF STEM CELLS on August 26, 2009 at 6:01 pm

Cord Blood America $1.6 Million in Debt Retired in Third Quarter 2009

SANTA MONICA, Calif., Aug 25, 2009 — Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has retired $1.6 million in debt since July 2009. The Company previously announced it retired $5 million in debt in the first half of 2009.

stemcells_money1“We have said that one of the pillars of strength for Cord Blood America in 2009 was to significantly reduce debt and we certainly are fulfilling this obligation to our shareholders,” said Matthew Schissler, founder and CEO. The Company also announced on August 5, 2009, that it retired $2.53 million of long-term debt with the payoff of two notes with the Shelter Island Opportunity Fund.

“Retirement of debt is good for our balance sheet and makes CBAI a better investment for our shareholders,” said Mr. Schissler. “We are pleased with a strengthened balance sheet, having recently announced second quarter results showing a significant increase in working capital and cash on hand.” About Cord Blood America Cord Blood America (OTC Bulletin Board: CBAI | Quote | Chart | News | PowerRating) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at http://www.corcell.com. For investor information, visit http://www.cordblood-america.com.

via BEEY,CBAI,CYDE,MBCI,NYMH,UBRG Www.standoutstocks.com: Stocks That Standout For 8/25/2009 Are UBRG, NYMH, CBAI, MBCI, CYDE.

Golden Dragon Holdings, Inc. (OTC:GDHI) Is The Top Traded O

In BUSINESS OF STEM CELLS on August 26, 2009 at 2:33 pm

Golden Dragon Holdings, Inc. (OTC:GDHI) Is The Top Traded OTC Stock

HARD TO TREAT DISEASES (PINK:HTDS) and IJJ CORP (PINK:IJJP) Round Out Top Three Percentage Gainers

Dallas, TX 8/26/2009 05:02 PM GMT (TransWorldNews)

Dallas, TX – WePickPennyStocks.com is pleased to alert investors of stocks on the move.

stemcells_money1HARD TO TREAT DISEASES (PINK:HTDS) is trading up 4% at $0.0118 on huge volume of 31 million shares. On 24 August, Hard to Treat Diseases Slavica Bio Chem http://www.slavicabiochem.com Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer Slavica BioChem reported that IBISS research group from Serbia has begun preliminary experiments within a project aimed at Promoting stem cell graft survival in the model of traumatic brain injury in rats. One of the goals of this project is to examine the potential role of Ribavirin in promoting survival of the stem cells transplanted after brain injury.

Golden Dragon Holdings, Inc. (OTC:GDHI) is also moving higher 23% at $0.0011 on very unusual volume of 77 million shares .Today August 26, Golden Dragon Holdings, Inc. announces that it has entered into a distribution agreement with Vosges, Ltd. http://www.vosgeschocolate.com a world leader in luxury gourmet chocolate and chocolate confessionary products. Under this agreement GDHI will exclusively place Vosges products in selectively hand-pick 5 star hotels in China.

IJJ CORP (PINK:IJJP) is trading up 250% at $0.0490 on huge volume of 2.29 million shares. today, August 26, JJ Corp. announced that the Company has acquired V-Clouds, a dynamic European technology company, for 4 million shares of IJJ Corp. (IJJC) restricted shares valued at $.25 per share from Cloud Technologies (Pink Sheets: CLDZ). V-Clouds’ main focus is in the Email Management and Security Space. The V-Clouds solution is for small businesses and large enterprises, as well as service providers. Dave Lovatt and Owen Dukes will remain with V-Clouds, with Dave Lovatt remaining on the Board as its President.

via Golden Dragon Holdings, Inc. (OTC:GDHI) Is The Top Traded O.

%d bloggers like this: